All In Biotech

Drug Trial Radar · NCT07372703

Study of the Safety, Tolerability, Pharmacokinetics of VV913 Capsules in Chinese Healthy Participants

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics of a Single Oral Dose of VV913 Capsules in Chinese Healthy Participants

Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

56

Planned (sponsor's estimate)

Start

Jan 29, 2026

Primary completion

Sep 2026

Study completion Oct 2026

Sponsor

Lead sponsor
Vigonvita Life SciencesIndustry
Sponsor type
Industry
First posted
Jan 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, single ascending-dose study to evaluate the safety, tolerability and pharmacokinetics characteristics of VV913 Capsules in healthy adults.

Conditions

  • Healthy Volunteers

Interventions

  • VV913 1mg groupDrug

    6 participants will receive VV913 1mg orally; 2 participants will receive placebo orally.

  • VV913 2mg groupDrug

    6 participants will receive VV913 2mg orally; 2 participants will receive placebo orally.

  • VV913 4mg groupDrug

    6 participants will receive VV913 4mg orally; 2 participants will receive placebo orally.

  • VV913 8mg groupDrug

    6 participants will receive VV913 8mg orally; 2 participants will receive placebo orally.

  • VV913 15mg groupDrug

    6 participants will receive VV913 15mg orally; 2 participants will receive placebo orally.

  • VV913 25mg groupDrug

    6 participants will receive VV913 25mg orally; 2 participants will receive placebo orally.

  • VV913 40mg groupDrug

    6 participants will receive VV913 40mg orally; 2 participants will receive placebo orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: 72 hours after administration
  2. TmaxTime frame: 72 hours after administration
  3. t1/2Time frame: 72 hours after administration
  4. AUC0-tTime frame: 72 hours after administration
  5. AUC0-∞Time frame: 72 hours after administration
  6. KelTime frame: 72 hours after administration
  7. Vd/FTime frame: 72 hours after administration
  8. MRTTime frame: 72 hours after administration
  9. CL/FTime frame: 72 hours after administration
  10. AE & SAETime frame: from day1 to day7 after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.